Table 1 Baseline characteristics
From: B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease
Characteristic | All N = 522 | BNP ≤ 100 pg/mL N = 407 | BNP > 100 pg/mL N = 115 | p value |
|---|---|---|---|---|
Median (IQR) or % | Median (IQR) or % | Median (IQR) or % | ||
Age, years | 66 (58–73) | 64 (56–71) | 70 (65–76) | < 0.0001 |
Women, % | 32.8% | 33.4% | 30.4% | NS |
Current smoker, % | 16.1% | 17.2% | 12.2% | NS |
Prior myocardial infarction, % | 22.2% | 20.9% | 27.0% | NS |
Prior revascularization, % | 20.9% | 19.9% | 24.3% | NS |
Diabetes mellitus, % | 22.0% | 23.3% | 17.4% | NS |
Left ventricular ejection fraction, %* | 64 (53–71) | 65 (58–72) | 53 (39–67) | < 0.0001 |
Left ventricular systolic dysfunction, % | 19.0% | 13.0% | 40.0% | < 0.0001 |
Body mass index, kg/m2 | 28 (25–31) | 28 (26–31) | 27 (25–31) | NS |
Systolic blood pressure, mmHg | 140 (129–156) | 139 (129–153) | 145 (131–161) | 0.019 |
Diastolic blood pressure, mmHg | 79 (72–86) | 79 (73–86) | 77 (69–85) | NS |
Central augmentation pressure, mmHg† | 16 (9–23) | 15 (9–22) | 20 (10–27) | 0.003 |
≥ 24 mmHg | 23.5% | 18.7% | 40.7% | 0.0002 |
Central pulse pressure, mmHg† | 50 (39–63) | 49 (39–61) | 56 (42–73) | 0.001 |
≥ 50 mmHg | 52.1% | 49.1% | 62.8% | 0.13 |
Total cholesterol, mmol/L | 4.5 (3.8–5.2) | 4.5 (3.9–5.4) | 4.1 (3.5–4.7) | < 0.0001 |
High-density lipoprotein cholesterol, mmol/L | 1.2 (1.0–1.4) | 1.2 (1.0–1.4) | 1.2 (1.0–1.5) | NS |
Estimated glomerular filtration rate, mL/min | 82 (68–97) | 85 (69–98) | 78 (60–93) | 0.002 |
Low-frequency heart rate variability, ms2 ‡ | 211 (72–470) | 213 (85–446) | 191 (27–1017) | NS |
> 250 ms2 | 56.5% | 57.4% | 52.7% | NS |
Total power heart rate variability, ms2 ‡ | 830 (323–1954) | 766 (360–1764) | 1101 (198–3150) | NS |
High-sensitivity C-reactive protein, mg/L⁋ | 1.9 (0.9–4.0) | 1.9 (0.8–3.9) | 2.1 (1.0–4.5) | NS |
> 3 mg/L | 32.4% | 31.9% | 34.2% | NS |
B-type natriuretic peptide, pg/mL | 40 (15–90) | 27 (12–53) | 188 (137–413) | – |
> 100 pg/mL | 22.0% | |||
> 400 pg/mL | 5.6% | |||
Framingham 10-year risk, % | 11 (8–20) | 11 (7–20) | 13 (8–20) | NS |
SCORE 10-year risk, % | 9 (4–17) | 8 (3–16) | 12 (7–22) | < 0.0001 |